GLPwatch

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

NCT03457012 · Completed

Last updated 2026-05-28

This study is testing how the medication semaglutide affects blood sugar levels in adults with type 2 diabetes as part of regular medical care in Canada.

Status Completed The study has finished.
Type Observational
Participants 462 people
Who can join Ages 18+ · all sexes
Timeline Started 2018-03 · est. completion 2019-12
Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT03457012 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about the health and the diabetes treatment. Participants will complete these during the normally scheduled visits with the study doctor.

Treatments tested

Main thing measuredChange in Glycated Haemoglobin A1c (HbA1c)
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03457012 ↗